Evidence map›Paper›PMID 26489631›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2015

Total triterpenoids from Ganoderma Lucidum suppresses prostate cancer cell growth by inducing growth arrest and apoptosis.

Tao Wang, Zi-Ping Xie, Zhan-Sen Huang, Hao Li, An-Yang Wei, Jin-Ming Di, Heng-Jun Xiao, Zhi-Gang Zhang, Liu-Hong Cai, Xin Tao and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. International journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. MMP26: A potential biomarker for prostate cancer.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Tao WangDepartment of Urology, Medical Center for Overseas Patients, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zi-Ping XieDepartment of Andrology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Zhan-Sen HuangDepartment of Infertility and Sexual Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510631, China.
Hao LiDepartment of Infertility and Sexual Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510631, China.
An-Yang WeiDepartment of Urology, Medical Center for Overseas Patients, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. profway@126.com.
Jin-Ming DiDepartment of Urology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, China. djm2000@eyou.com.
Heng-Jun XiaoDepartment of Urology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, China. hjxiao555@126.com.
Zhi-Gang ZhangDepartment of Pathology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. binglike2000@aliyun.com.
Liu-Hong CaiCenter for Reproductive Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. 4468700-80@qq.com.
Xin TaoCenter for Reproductive Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. taoxqz@yeah.net.
Tao QiDepartment of Infertility and Sexual Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510631, China. 185630886@qq.com.
Di-Ling ChenState Key Laboratory of Applied Microbiology, South China, Guangdong Institute of Microbiology, Guangzhou, 510070, China. diling1983@163.com.
Jun ChenDepartment of Infertility and Sexual Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510631, China. jchen121121@hotmail.com.
Sun Yat-sen University · CNThird Affiliated Hospital of Sun Yat-sen University · CNSouthern Medical University · CNHubei University of Medicine · CNInstitute of Microbiology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, one immortalized human normal prostatic epithelial cell line (BPH) and four human prostate cancer cell lines (LNCaP, 22Rv1, PC-3, and DU-145) were treated with Ganoderma Lucidum triterpenoids (GLT) at different doses and for different time periods. Cell viability, apoptosis, and cell cycle were analyzed using flow cytometry and chemical assays. Gene expression and binding to DNA were assessed using real-time PCR and Western blotting. It was found that GLT dose-dependently inhibited prostate cancer cell growth through induction of apoptosis and cell cycle arrest at G1 phase. GLT-induced apoptosis was due to activation of Caspases-9 and -3 and turning on the downstream apoptotic events. GLT-induced cell cycle arrest (mainly G1 arrest) was due to up-regulation of p21 expression at the early time and down-regulation of cyclin-dependent kinase 4 (CDK4) and E2F1 expression at the late time. These findings demonstrate that GLT suppresses prostate cancer cell growth by inducing growth arrest and apoptosis, which might suggest that GLT or Ganoderma Lucidum could be used as a potential therapeutic drug for prostate cancer.

Indexed as

Gene Expression Regulation, NeoplasticAntineoplastic Agents, PhytogenicApoptosisCaspase 3Caspase 9Cell Line, TumorCell SurvivalCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase Inhibitor p21Dose-Response Relationship, DrugE2F1 Transcription FactorG1 Phase Cell Cycle CheckpointsHumansMaleNucleosomesAntineoplastic Agents, PhytogenicCASP3 protein, humanCASP9 protein, humanCaspase 3Caspase 9CCND1 protein, humanCDK4 protein, humanCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase Inhibitor p21E2F1 protein, humanE2F1 Transcription FactorNucleosomesPlant ExtractsTriterpenesapoptosiscell cycle arrestGanoderma Lucidum triterpenoidsprostate cancer

Identifiers

PMID26489631
OpenAlexW2172919837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.